ArticleEnvironmental science and pollution research international2014
Acute toxicity of arsenic to Aliivibrio fischeri (Microtox bioassay) as influenced by potential competitive-protective agents.
Article in Environmental science and pollution research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Biotic and Abiotic Factors Influencing Arsenic Biogeochemistry and Toxicity in Fluvial Ecosystems: A Review.International journal of environmental research and public health · 2020Review
- Use of red mud (bauxite residue) for the retention of aqueous inorganic mercury(II).Environmental science and pollution research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the effect of some potential alleviative compounds against the acute toxicity of arsenic (As(V), As(III) and DMA(V)) on Aliivibrio fischeri (formerly Vibrio fischeri), a bioluminescent model bacterium, through the Microtox bioassay. The compounds studied differed in their mechanism of action, and they included the following: phosphate and glycerol, as chemical analogues (and potential competitors) of As(V) or As(III), respectively; citrate, a weak natural organic ligand; and the antioxidant ascorbic acid. Special attention was paid to phosphate effects, a widespread pollutant in natural environments. As(V) was found to be more acutely toxic than As(III) to A. fischeri, in accordance with its higher interaction with the bacteria. Both As(V) and As(III) were found to be much more acutely toxic than DMA(V), which was essentially non-acutely toxic even at very high concentrations. Phosphate presence (at equimolar P/As ratios or higher) resulted in the almost total suppression of bioluminescence inhibition, suggesting it exerts an alleviative effect against As(V) acute toxicity on A. fischeri. Interestingly, the uptake and the percentage of extracellular As(V) were not affected by the addition of phosphate, suggesting that such protective effect does not result from the competition for their common transporters. In contrast, the acute toxicity of As(III) was essentially unaffected by phosphate. Glycerol did not decrease the acute toxicity or the uptake of As(III) by A. fischeri, denoting the likely occurrence of an additional mechanism for As(III) uptake in such bacteria. Similarly, citrate and ascorbic acid essentially did not caused alleviation of As(V) or As(III) acute toxicity. As for environmental and operational implications, P could beneficially protect aquatic microorganisms against acute detrimental effects of As(V), whilst its presence could mask the toxicity due to As(V) when assessed using the Microtox bioassay, thus leading to seriously underestimate the actual ecological and health risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.